Ser217leu polymorphism of the HPC2/ELAC2 gene associated with prostatic cancer risk in Japanese men

被引:15
|
作者
Takahashi, H
Lu, W
Watanabe, M
Katoh, T
Furusato, M
Tsukino, H
Nakao, H
Sudo, A
Suzuki, H
Akakura, K
Ikemoto, I
Asano, K
Ito, T
Wakui, S
Muto, T
Hano, H
机构
[1] Jikei Univ, Sch Med, Dept Pathol, Minato Ku, Tokyo 1058641, Japan
[2] Mie Univ, Sch Med, Dept Pathol 2, Mie, Japan
[3] Miyazaki Med Coll, Dept Publ Hlth, Miyazaki 88916, Japan
[4] Kyorin Univ, Sch Med, Dept Pathol, Tokyo, Japan
[5] Chiba Univ, Sch Med, Dept Urol, Chiba 260, Japan
[6] Jikei Univ, Sch Med, Dept Urol, Tokyo 1058641, Japan
[7] Tokyo Med Univ, Dept Urol, Tokyo, Japan
关键词
tumor suppressor gene; familial prostatic cancer; mutation; single nucleotide polymorphism; risk factor;
D O I
10.1002/ijc.11347
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The HPC2/ELAC2 gene may be associated with hereditary/familial prostate cancer (PCa). Two common missense variants (Ser217Leu and Ala541Thr) have been reported in the gene. We performed mutational, allelotyping and expression analyses and a molecular epidemiological study to clarify the relations between this gene and prostatic diseases, including PCa and benign prostatic hyperplasia (BPH) in Japanese men. We screened for mutations in 109 patients with PCa including 11 patients from 1 hereditary and 9 familial PCa. Loss of heterozygosity and expression were analyzed. An epidemiological study was done in sporadic PCa (n=98) and BPH (n= 143) using 1 novel (Ser627Leu) and 2 previously described polymorphisms of the HPC2/ELAC2 gene. Somatic or germline mutations were not confirmed in any cases of PCa Loss of heterozygosity at 2 microsatellites, DI7S1289 and DI7S520, was detected in 1 of 38 and 1 of 35 cases, respectively. Expression analysis revealed decreased or absent mRNA expression in 6 of 38 tumors. Epidemiologic analysis showed that a Leu allele at codon 217 was significantly more frequent in patients with PCa than in controls (10.2% vs. 3.5% odds ratio = 3.11; 95% confidence interval, 1.22-7.90). At codon 541, all patients with PCa or BPH and all control subjects had the Ala/Ala genotype. At codon 627, the incidence of the Leu variant was slightly, but not significantly, higher in patients with BPH than in controls (7.0% vs. 2.8% , odds ratio = 239, 95% confidence interval, 0.94-7.13, not statistically significant). We concluded that germline/somatic mutations of HPC2/ELAC2 are uncommon in PCa. Similarly, allelic imbalances at the gene locus and changes in expression are rare. Although no difference in allele frequency at Ser217Leu between patients with PCa and controls has been reported in a Western population, this polymorphism is a potential indicator of PCa risk in Japanese men and it should be examined in other ethnic groups. (C) 2003 Wiley-Liss, Inc.
引用
收藏
页码:224 / 228
页数:5
相关论文
共 50 条
  • [1] HPC2/ELAC2 polymorphism associated with Japanese sporadic prostate cancer
    Yokomizo, A
    Koga, H
    Kinukawa, N
    Tsukamoto, T
    Hirao, Y
    Akaza, H
    Mori, M
    Naito, S
    PROSTATE, 2004, 61 (03): : 248 - 252
  • [2] Meta-analysis of associations of the Ser217Leu and Ala541Thr variants in ELAC2 (HPC2) and prostate cancer
    Camp, NJ
    Tavtigian, SV
    AMERICAN JOURNAL OF HUMAN GENETICS, 2002, 71 (06) : 1475 - 1478
  • [3] Association of HPC2/ELAC2 polymorphism with prostate cancer risk in a Japanese population
    Suzuki, K
    Ohtake, N
    Nakata, S
    Takei, T
    Matsui, H
    Ono, Y
    Nakazato, H
    Hasumi, M
    Koike, H
    Ito, K
    Fukabori, Y
    Kurokawa, K
    Yamanaka, H
    ANTICANCER RESEARCH, 2002, 22 (6B) : 3507 - 3511
  • [4] HPC2/ELAC2 gene variants associated with incident prostate cancer
    David Adler
    Nimira Kanji
    Kiril Trpkov
    Gordon Fick
    Rhiannon M. Hughes
    Journal of Human Genetics, 2003, 48 : 634 - 638
  • [5] HPC2/ELAC2 gene variants associated with incident prostate cancer
    Adler, D
    Kanji, N
    Trpkov, K
    Fick, G
    Hughes, RM
    JOURNAL OF HUMAN GENETICS, 2003, 48 (12) : 634 - 638
  • [6] Prevalence of the Ser217Leu Variant of the ELAC2 Gene and Its Association with Prostate Cancer in Population of the Littoral Region of Cameroon
    Djomkam, Alexandra Lindsey Zune
    Beyeme Sala, Theodore
    Baari Memba, Clarisse
    Njimoh, Dieudonne Lemuh
    PROSTATE CANCER, 2019, 2019
  • [7] Association of HPC2/ELAC2 genotypes and prostate cancer
    Rebbeck, TR
    Walker, AH
    Zeigler-Johnson, C
    Weisburg, S
    Martin, AM
    Nathanson, KL
    Wein, AJ
    Malkowicz, SB
    AMERICAN JOURNAL OF HUMAN GENETICS, 2000, 67 (04) : 1014 - 1019
  • [8] Carriage of Ser217Leu and Ala541Thr Variants of ELAC2 Gene and Risk Factors in Patients with Prostate Cancer in Burkina Faso
    Traore, Aida Dje Djeneba
    Ky, Bienvenu Desire
    Traore, Lassina
    Zohoncon, Theodora M.
    Zoure, Abdou Azaque
    Yonli, Albert Theophane
    Sombie, Herman Karim
    Sorgho, Pegdwende Abel
    Elvira Bazie, Bapio Valery Jean Telesphore
    Tovo, Sessi Frida Appoline
    Kadanga, Essonan
    Bakyono, Belele Simeon
    Traore, Kalifou
    Ouedraogo, Teega-Wende Clarisse
    Djigma, Florencia W.
    Simpore, Jacques
    PROSTATE CANCER, 2022, 2022
  • [9] Association of HPC2/ELAC2 missense variants with risk breast cancer
    Neuhausen, SL
    Csokay, B
    Nathanson, K
    Farnham, J
    Camp, NJ
    Rebbeck, T
    Weber, B
    Tavtigian, S
    Cannon-Albright, L
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 185 - 186
  • [10] Role of HPC2/ELAC2 in hereditary prostate cancer
    Wang, L
    McDonnell, SK
    Elkins, DA
    Slager, SL
    Christensen, E
    Marks, AF
    Cunningham, JM
    Peterson, BJ
    Jacobsen, SJ
    Cerhan, JR
    Blute, ML
    Schaid, DJ
    Thibodeau, SN
    CANCER RESEARCH, 2001, 61 (17) : 6494 - 6499